Component: (Network and Table)
Network
00400 - Statement - Condensed Consolidated Statements of Cash Flows
(http://www.immunomedics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0000722830 (http://www.sec.gov/CIK)
Condensed Consolidated Statements of Cash Flows [Abstract]Period [Axis]
2015-07-01 - 2016-06-30
2014-07-01 - 2015-06-30
2013-07-01 - 2014-06-30
Condensed Consolidated Statements of Cash Flows [Abstract]
 
 
 
Cash flows from operating activities:
 
 
 
Net loss
(59,135,716) 
(48,123,971) 
(35,531,178) 
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization
737,661  
578,066  
569,442  
Amortization of deferred revenue
(202,088) 
(5,712) 
(2,674,347) 
Amortization of bond premiums
669,858  
544,208  
228,211  
Amortization of debt issuance costs
729,821  
281,791  
 
Amortization of deferred rent
99,516  
99,516  
99,516  
Gain on sale of marketable securities
(1,844) 
(11,015) 
(7,517) 
Increase (decrease) in allowance for doubtful accounts
20,369  
(34,432) 
39,344  
Non-cash expense related to stock compensation
3,740,526  
2,788,677  
3,218,050  
Non-cash decrease in value of life insurance policy
20,566  
155,544  
18,722  
Changes in operating assets and liabilities:
 
 
 
Accounts receivable
(190,300) 
271,820  
(62,652) 
Inventory
256,381  
328,126  
204,386  
Other receivables
620,300  
(553,966) 
(130,634) 
Prepaid expenses
97,948  
478,794  
(1,182,237) 
Other current assets
761,803  
(776,975) 
1,450,494  
Accounts payable and accrued expenses
3,147,606  
4,946,099  
2,935,816  
Deferred revenues
165,793  
37,221  
134,196  
Net cash used in operating activities
(48,461,800) 
 
(38,996,209) 
 
(30,690,388) 
 
Cash flows from investing activities:
 
 
 
Purchases of marketable securities
(2,749,117) 
(86,307,071) 
(44,116,046) 
Proceeds from sales/maturities of marketable securities
50,850,088  
34,491,153  
9,024,145  
Purchases of property and equipment
(2,226,256) 
(924,429) 
(378,006) 
Proceeds from partial liquidation of life insurance policy
  
400,000  
Net cash provided by (used in) investing activities
45,874,715  
 
(52,740,347) 
 
(35,069,907) 
 
Cash flows from financing activities:
 
 
 
Proceeds from issuance of convertible senior notes
 
100,000,000  
 
Payment of debt issuance costs
 
(3,657,215) 
 
Issuance of common stock, net of fees
  
29,809,448  
Exercise of stock options
2,732,962  
2,959,930  
1,799,353  
Tax withholding payments for stock compensation
(368,984) 
(585,725) 
(331,732) 
Net cash provided by financing activities
2,363,978  
 
98,716,990  
 
31,277,069  
 
Effect of changes in exchange rates on cash and cash equivalents
(26,043) 
(489,153) 
118,720  
Net (decrease) increase in cash and cash equivalents
(249,150) 
 
6,491,281  
 
(34,364,506) 
 
Cash and cash equivalents beginning of period
13,452,775  
6,961,494  
41,326,000  
Cash and cash equivalents end of period
13,203,625  
 
13,452,775  
 
6,961,494  
 
Supplemental disclosure of cash flow information:
 
 
 
Interest paid
4,802,778  
  
Cash paid for income taxes
28,679  
75,598  
136,973